A comprehensive review in "Biofunct. Mater." meticulously details the most recent advancements and clinical translation of intelligent nanodrugs for breast cancer treatment. This paper presents an exhaustive overview of subtype-specific nanostrategies, the clinical benefits of FDA-approved nanodrugs, and innovative approaches to address tumor heterogeneity and treatment resistance. This serves as a foundational framework and pragmatic guide for enhancing precision-based breast cancer therapies.

Numerous studies have demonstrated a strong link between the human microbiome and the progression of various diseases, including obesity, diabetes, hypertension, and malignant tumors. A 2018 study attributed 13% of global cancer incidence to microorganisms. Intra-tumoral microorganisms (those residing within tumors) have been reported in a variety of major cancers and are closely associated with tumor type, initiation, progression, immune regulation, and therapeutic outcome.

In a comprehensive review published in the journal Immunity & Inflammation, a research team led by Professor Tao Dong at the University of Oxford systematically dissects the central role of T cells in anti-tumor immunity and sheds light on the next-generation cancer immunotherapies. The article, titled "Leveraging T cells for cancer immunotherapy," summarizes current understanding and highlights promising strategies to overcome the challenges that limit the efficacy of current treatments.

A recent randomized controlled pilot study suggests that Baduanjin, a traditional Chinese mind-body exercise, may help alleviate menopausal symptoms and fatigue in breast cancer patients undergoing aromatase inhibitor therapy. The study, published in Translational Exercise Biomedicine (ISSN: 2942-6812), an official partner journal of International Federation of Sports Medicine (FIMS).

Researchers at Rice University have engineered living cells to use a 21st amino acid that illuminates protein changes in real time, providing a new method for observing changes within cells. The technique is effective in bacteria, human cells and live tumor models, making it possible to study complex diseases like cancer more ethically. The findings are pending publication in Nature Communications Oct. 23.

The Alliance for Clinical Trials in Oncology has launched a new clinical trial to explore if using two targeted medications can help slow tumor growth in people with advanced adrenocortical carcinoma (ACC), a rare and aggressive cancer of the adrenal glands. In the study (Alliance A092204), researchers will test whether combining two medications (cabozantinib and cemiplimab) can help slow the growth of ACC and improve outcomes for patients whose cancer has spread or returned after treatment.